Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 2/2007

01-02-2007 | Review Article

Treatment Approaches for Painful Bladder Syndrome/Interstitial Cystitis

Author: Dr Theoharis C. Theoharides

Published in: Drugs | Issue 2/2007

Login to get access

Abstract

Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disease of unknown aetiology, characterised by severe pressure and pain in the bladder area or lower pelvis that is frequently or typically relieved by voiding, along with urgency or frequency of urination in the absence of urinary tract infections. PBS/IC occurs primarily in women, is increasingly recognised in young adults, and may affect as many as 0.1–1% of adult women. PBS/IC is often comorbid with allergies, endometriosis, fibromyalgia, irritable bowel syndrome and panic syndrome, all of which are worsened by stress. As a result, patients may visit as many as five physicians, including family practitioners, internists, gynaecologists, urologists and pain specialists, leading to confusion and frustration. There is no curative treatment; intravesical dimethyl sulfoxide, as well as oral amitriptyline, pentosan polysulfate and hydroxyzine have variable results, with success more likely when these drugs are given together. Pilot clinical trials suggest that the flavonoid quercetin may be helpful. Lack of early diagnosis and treatment can affect outcomes and leads to the development of hyperalgesia/allodynia.
Literature
1.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002 Jul; 187 (1): 116–26PubMedCrossRef
2.
Hanno P, Keay S, Moldwin R, et al. International Consultation on IC-Rome, September 2004/Forging an International Consensus: progress in painful bladder syndrome/interstitial cystitis. Report and abstracts. Int Urogynecol J Pelvic Floor Dysfunct 2005 Jun; 16 Suppl. 1: S2–34PubMedCrossRef
3.
Hanno P. Interstitial cystitis and related disorders. In: Walsh PC, editor. Campbell’s urology. Philadelphia (PA): Elsevier, 2002: 631–68
4.
Lukban JC, Whitmore KE, Sant GR. Current management of interstitial cystitis. Urol Clin North Am 2002; 29: 649–60PubMedCrossRef
5.
Forrest JB, Schmidt S. Interstitial cystitis, chronic nonbacterial prostatitis and chronic pelvic pain syndrome in men: a common and frequently identical clinical entity. J Urol 2004; 172: 2561–2PubMedCrossRef
6.
Nordling J, Anjum FH, Bade JJ, et al. Primary evaluation of patients suspected of having interstitial cystitis (IC). Eur Urol 2004 May; 45 (5): 662–9PubMedCrossRef
7.
Ottem DP, Teichman JM. What is the value of cystoscopy with hydrodistension for interstitial cystitis? Urology 2005 Sep; 66 (3): 494–9PubMedCrossRef
8.
FitzGerald MP, Brensinger C, Brubaker L, et al. What is the pain of interstitial cystitis like? Int Urogynecol J Pelvic Floor Dysfunct 2006 Jan; 17 (1): 69–72PubMedCrossRef
9.
Shulman LP. Chronic pelvic pain and the role of pain of bladder origin: changing the paradigm to improve clinical outcomes. Int J Fertil Womens Med 2005 Mar; 50 (2): 73–8PubMed
10.
Stanford EJ, Koziol J, Feng A. The prevalence of interstitial cystitis, endometriosis, adhesions, and vulvar pain in women with chronic pelvic pain. J Minim Invasive Gynecol 2005; 12: 43–9PubMedCrossRef
11.
Paulson JD, Delgado M. Chronic pelvic pain: the occurrence of interstitial cystitis in a gynecological population. 1. J Soc Lapar Surg 2005 Oct; 9 (4): 426–30
12.
Chung MK, Chung RP, Gordon D. Interstitial cystitis and endometriosis in patients with chronic pelvic pain: the “evil twins” syndrome. J Soc Lapar Surg 2005 Jan; 9 (1): 25–9
13.
Sand PK. Chronic pain syndromes of gynecologic origin. J Reprod Med 2004; 49: 230–4PubMed
14.
Parsons CL, Dell J, Stanford EJ, et al. The prevalence of interstitial cystitis in gynecologic patients with pelvic pain, as detected by intravesical potassium sensitivity. Am J Obstet Gynecol 2002 Nov; 187 (5): 1395–400PubMedCrossRef
15.
Nordling J. ESSIC classification of PBS/BPS. NIDDK International Conference: frontiers in painful bladder syndrome and interstitial cystitis; 2006 Oct 25; Bethesda (MD)
16.
Ness TJ, Powell-Boone T, Cannon R, et al. Psychophysical evidence of hypersensitivity in subjects with interstitial cystitis. J Urol 2005; 173: 1983–7PubMedCrossRef
17.
O’Leary MP, Sant GR, Fowler FJJr, et al. The interstitial cystitis symptom index and problem index. Urology 1997; 49 Suppl. 5A: 58–63PubMedCrossRef
18.
Sirinian E, Azevedo K, Payne CK. Correlation between 2 interstitial cystitis symptom instruments. J Urol 2005; 173: 835–40PubMedCrossRef
19.
Propert KJ, Mayer RD, Wang Y, et al. Responsiveness of symptom scales for interstitial cystitis. Urology 2006 Jan; 67 (1): 55–9PubMedCrossRef
20.
Parsons CL, Dell J, Stanford EJ, et al. Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology 2002; 60: 573–8PubMedCrossRef
21.
Rothrock NE, Lutgendorf SK, Kreder KJ, et al. Stress and symptoms in patients with interstitial cystitis: a life stress model. Urology 2001; 57: 422–7PubMedCrossRef
22.
Weissman MM, Gross R, Fyer A, et al. Interstitial cystitis and panic disorder: a potential genetic syndrome. Arch Gen Psychiatry 2004; 61: 273–9PubMedCrossRef
23.
Gillespie L. Metabolic appraisal of the effects of dietary modification on hypersensitive bladder symptoms. Br J Urol 1993 Sep; 72 (3): 293–7PubMed
24.
Bade JJ, Peeters JMC, Mensink HJA. Is the diet of patients with interstitial cystitis related to their disease? Eur Urol 1997; 32: 179–83PubMed
25.
Kennedy CM, Bradley CS, Galask RP, et al. Risk factors for painful bladder syndrome in women seeking gynecologic care. Int Urogynecol J Pelvic Floor Dysfunct 2006 Jan; 17 (1): 73–8PubMedCrossRef
26.
Nguan C, Franciosi LG, Butterfield NN, et al. A prospective, double-blind, randomized cross-over study evaluating changes in urinary pH for relieving the symptoms of interstitial cystitis. BJU Int 2005; 95: 91–4PubMedCrossRef
27.
Wu EQ, Birnbaum H, Mareva M, et al. Interstitial cystitis: cost, treatment and co-morbidities in an employed population. Pharmacoeconomics 2006; 24 (1): 55–65PubMedCrossRef
28.
Theoharides TC, Pang X, Letourneau R, et al. Interstitial cystitis: a neuroimmunoendocrine disorder. Ann N Y Acad Sci 1998; 840: 619–34PubMedCrossRef
29.
Koziol JA, Clark DC, Gittes RF, et al. The natural history of interstitial cystitis: a survey of 374 patients. J Urol 1993; 149: 465–9PubMed
30.
Alagiri M, Chottiner S, Ratner V, et al. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology 1997; 49: 52–7PubMedCrossRef
31.
Erickson DR, Morgan KC, Ordille S, et al. Nonbladder related symptoms in patients with interstitial cystitis. J Urol 2001; 166: 557–62PubMedCrossRef
32.
Peeker R, Atansiu L, Logadottir Y. Intercurrent autoimmune conditions in classic and non-ulcer interstitial cystitis. Scand J Urol Nephrol 2003; 137: 60–3CrossRef
33.
Yamada T. Significance of complications of allergic diseases in young patients with interstitial cystitis. Int J Urol 2003 Oct; 10 Suppl.: S56–8PubMedCrossRef
34.
Novi JM, Jeronis S, Srinivas S, et al. Risk of irritable bowel syndrome and depression in women with interstitial cystitis: a case-control study. J Urol 2005 Sep; 174 (3): 937–40PubMedCrossRef
35.
Harlow BL, Stewart EG. A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? J Am Med Womens Assoc 2003; 58 (2): 82–8PubMed
36.
Hanno PM, Levin RM, Monson FC, et al. Diagnosis of interstitial cystitis. J Urol 1990; 143: 278–81PubMed
37.
Kusek JW, Nyberg LM. The epidemiology of interstitial cystitis: is it time to expand our definition? Urology 2001; 57: 95–9PubMedCrossRef
38.
Curhan GC, Speizer FE, Hunter DJ, et al. Epidemiology of interstitial cystitis: a population based study. J Urol 1999; 161: 549–52PubMedCrossRef
39.
Leppilahti M, Sairanen J, Tammela TL, et al. Prevalence of clinically confirmed interstitial cystitis in women: a population based study in Finland. J Urol 2005 Aug; 174 (2): 581–3PubMedCrossRef
40.
Rosenberg MT, Hazzard M. Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urol 2005 Dec; 174 (6): 2231–4PubMedCrossRef
41.
Farkas A, Waisman J, Goodwin WE. Interstitial cystitis in adolescent girls. J Urol 1977; 118: 837–8PubMed
42.
Mattox TF. Interstitial cystitis in adolescents and children: a review. J Pediatr Adolesc Gynecol 2004; 17: 7–11PubMedCrossRef
43.
44.
Selo-Ojeme DO, Paranjothy S, Onwude JL. Interstitial cystitis coexisting with vulvar vestibulitis in a 4-year-old girl. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13: 261–2PubMedCrossRef
45.
La Manna A, Polito C, Papale MR, et al. Chronic interstitial cystitis and systemic lupus erythematosus in an 8-year-old girl. Pediatr Nephrol 2005; 12: 139–40CrossRef
46.
Shear S, Mayer R. Development of glomerulations in younger women with interstitial cystitis. Urology 2006 Aug; 68 (2): 253–6PubMedCrossRef
47.
Warren JW, Jackson TL, Langenberg P, et al. Prevalence of interstitial cystitis in first-degree relatives of patients with interstitial cystitis. Urology 2004; 63: 17–21PubMedCrossRef
48.
Warren JW, Keay SK, Meyers D, et al. Concordance of interstitial cystitis in monozygotic and dizygotic twin pairs. Urology 2001; 57: 22–5PubMedCrossRef
49.
Hamilton SP, Fyer AJ, Durner M, et al. Further genetic evidence for a panic disorder syndrome mapping to chromosome 13q. Proc Natl Acad Sci U S A 2003; 100: 2550–5PubMedCrossRef
50.
Turner KJ, Stewart LH. How do you stretch a bladder? A survey of UK practice, a literature review, and a recommendation of a standard approach. Neurourol Urodyn 2005; 24 (1): 74–6PubMedCrossRef
51.
Erickson DR, Tomaszewski JE, Kunselman AR, et al. Do the National Institute of Diabetes and Digestive and Kidney Diseases cystoscopic criteria associate with other clinical and objective features of interstitial cystitis? J Urol 2005; 173: 93–7PubMedCrossRef
52.
Hanno P, Baranowski A, Fall M, et al. Painful bladder syndrome (including interstitial cystitis). In: Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. Plymouth: Health Publication, 2005: 1457–520
53.
Irwin P, Samsudin A. Reinvestigation of patients with a diagnosis of interstitial cystitis: common things are sometimes common. J Urol 2005 Aug; 174 (2): 584–7PubMedCrossRef
54.
Kaufman RH, Friedrich EG, Gardner HL. Non-neoplastic epithelial disorders of the vulvar skin and mucosa; miscellaneous vulvar disorders. In: Kaufman RH, Friedrich EG, Gardner HL, editors. Benign diseases of the vulva and vagina. Chicago (IL): Chicago Yearbook, 1989: 299–360
55.
el-Mansoury M, Boucher W, Sant GR, et al. Increased urine histamine and methylhistamine in interstitial cystitis. J Urol 1994; 152: 350–3PubMed
56.
Boucher W, El-Mansoury M, Pang X, et al. Elevated mast cell tryptase in urine of interstitial cystitis patients. Br J Urol 1995; 76: 94–100PubMedCrossRef
57.
Lotz M, Villiger P, Hugli T, et al. Interleukin-6 and interstitial cystitis. J Urol 1994; 152: 869–73PubMed
58.
Erickson DR, Xie SX, Bhavanandan VP, et al. A comparison of multiple urine markers for interstitial cystitis. J Urol 2002; 167: 2461–9PubMedCrossRef
59.
Keay SK, Zhang CO, Shoenfelt J, et al. Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis. Urology 2001; 57: 9–14PubMedCrossRef
60.
Keay S, Zhang CO, Chai T, et al. Antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor in men with interstitial cystitis versus chronic pelvic pain syndrome. Urology 2004; 63: 22–6PubMedCrossRef
61.
Zhang CO, Li ZL, Kong CZ. APF, HB-EGF, and EGF biomarkers in patients with ulcerative vs. non-ulcerative interstitial cystitis. BMC Urol 2005 Apr 29; 5 (1): 7CrossRef
62.
Keay SK, Szekely Z, Conrads TP, et al. An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proc Natl Acad Sci U S A 2004; 101: 11803–8PubMedCrossRef
63.
Keay S, Seillier-Moiseiwitsch F, Zhang CO, et al. Changes in human bladder epithelial cell gene expression associated with interstitial cystitis or antiproliferative factor treatment. Physiol Genomics 2003; 14: 107–15PubMed
64.
Waxman JA, Sulak PJ, Kuehl TJ. Cystoscopic findings consistent with interstitial cystitis in normal women undergoing tubal ligation. J Urol 1998; 160: 1663–7PubMedCrossRef
65.
Lamale LM, Lutgendorf SK, Hoffman AN, et al. Symptoms and cystoscopic findings in patients with untreated interstitial cystitis. Urology 2006 Feb; 67 (2): 242–5PubMedCrossRef
66.
Bade J, Ishizuka O, Yoshida M. Future research needs for the definition/diagnosis of interstitial cystitis. Int J Urol 2003 Oct; 10 Suppl.: S31–4PubMedCrossRef
67.
Logadottir YR, Ehren I, Fall M, et al. Intravesical nitric oxide production discriminates between classic and nonulcer interstitial cystitis. J Urol 2004; 171: 1148–50PubMedCrossRef
68.
Payne CK, Terai A, Komatsu K. Research criteria versus clinical criteria for interstitial cystitis. Int J Urol 2003 Oct; 10 Suppl.: S7–10PubMedCrossRef
69.
Theoharides TC, Sant GR. Hydroxyzine therapy for interstitial cystitis. Urology (Suppl) 1997; 49: 108–10CrossRef
70.
Parsons CL, Bullen M, Kahn BS, et al. Gynecologic presentation of interstitial cystitis as detected by intravesical potassium sensitivity. Obstet Gynecol 2001 Jul; 98 (1): 127–32PubMedCrossRef
71.
Driscoll A, Teichman JM. How do patients with interstitial cystitis present? J Urol 2001; 166: 2118–20PubMedCrossRef
72.
Agarwal M, Dixon RA. A study to detect Helicobacter pylori in fresh and archival specimens from patients with interstitial cystitis, using amplification methods. BJU Int 2003; 91: 814–6PubMedCrossRef
73.
Agarwal M, Dixon RA. A study to detect Gardnerella vaginalis DNA in interstitial cystitis. BJU Int 2001; 88: 868–70PubMedCrossRef
74.
Al-Hadithi HN, Williams H, Hart CA, et al. Absence of bacterial and viral DNA in bladder biopsies from patients with interstitial cystitis/chronic pelvic pain syndrome. J Urol 2005 Jul; 174 (1): 151–4PubMedCrossRef
75.
Domingue GJ, Ghoniem GM, Bost KL, et al. Dormant microbes in interstitial cystitis. J Urol 1995; 153: 1321–6PubMedCrossRef
76.
Keay S, Zhang CO, Baldwin BR, et al. Polymerase chain reaction amplification of bacterial 16s rRNA genes in prostate biopsies from men without chronic prostatitis. Urology 1999 Mar; 53 (3): 487–91PubMedCrossRef
77.
Parsons CL, Stauffer C, Schmidt JD. Bladder-surface glycosaminoglycans: an efficient mechanism of environmental adaptation. Science 1980; 208: 605–7PubMedCrossRef
78.
Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 1991; 145: 732–5PubMed
79.
Wei DC, Politano VA, Selzer MG, et al. The association of elevated urinary total to sulfated glycosaminoglycan ratio and high molecular mass hyaluronic acid with interstitial cystitis. J Urol 2000; 163: 1577–83PubMedCrossRef
80.
Erickson DR, Sheykhnazari M, Ordille S, et al. Increased urinary hyaluronic acid and interstitial cystitis. J Urol 1998; 160: 1282–4PubMedCrossRef
81.
Moskowitz MO, Byrne DS, Callahan HJ, et al. Decreased expression of a glycoprotein component of bladder surface mucin (GP1) in interstitial cystitis. J Urol 1994; 151: 343–5PubMed
82.
Lokeshwar VB, Selzer MG, Cerwinka WH, et al. Urinary uronate and sulfated glycosaminoglycan levels: markers for interstitial cystitis severity. J Urol 2005 Jul; 174 (1): 344–9PubMedCrossRef
83.
Lokeshwar VB, Selzer MG, Unwala DJ, et al. Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity. J Urol 2006 Sep; 176 (3): 1001–7PubMedCrossRef
84.
Chelsky MJ, Rosen SI, Knight LC, et al. Bladder permeability in interstitial cystitis is similar to that of normal volunteers: direct measurement by transvesical absorption of 99mtechnetium-diethylenetriaminepentaacetic acid. J Urol 1994; 151: 346–9PubMed
85.
Elbadawi A, Light JK. Distinctive ultrastructural pathology of nonulcerative interstitial cystitis. Urol Int 1996; 56: 137–62PubMedCrossRef
86.
Zhang CO, Wang JY, Koch KR, et al. Regulation of tight junction proteins and bladder epithelial paracellular permeability by an antiproliferative factor from patients with interstitial cystitis. J Urol 2005 Dec; 174 (6): 2382–7PubMedCrossRef
87.
Erickson DR, Belchis DA, Dabbs DJ. Inflammatory cell types and clinical features of interstitial cystitis. Urology 1997; 158: 790–3CrossRef
88.
Leppilahti M, Hellstrom P, Tammela TL. Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology 2002; 60: 46–51PubMedCrossRef
89.
Green M, Filippou A, Sant G, et al. Expression of intercellular adhesion molecules in the bladder of patients with interstitial cystitis. Urology 2004; 63: 1–6CrossRef
90.
Felsen D, Frye S, Trimble LA, et al. Inflammatory mediator profile in urine and bladder wash fluid of patients with interstitial cystitis. Urology 1994; 152: 355–61
91.
Abdel-Mageed AB, Ghoniem GM. Potential role of rel/nuclear factor-kappaB in the pathogenesis of interstitial cystitis. J Urol 1998; 160 (6 Pt 1): 2000–3PubMedCrossRef
92.
Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology 2001; 57 Suppl. 6A: 47–55PubMedCrossRef
93.
Peeker R, Enerbäck L, Fall M, et al. Recruitment, distribution and phenotypes of mast cells in interstitial cystitis. Urology 2000; 163: 1009–15CrossRef
94.
Tomaszewski JE, Landis JR, Russack V, et al. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. Urology 2001; 57 Suppl. 6A: 67–81PubMedCrossRef
95.
Pang X, Boucher W, Triadafilopoulos G, et al. Mast cell and substance P-positive nerve involvement in a patient with both irritable bowel syndrome and interstitial cystitis. Urology 1996; 47: 436–8PubMedCrossRef
96.
Kisman OK, Lycklama ta Nijeholt AAB, van Krieken JHJM. Mast cell infiltration in intestine used for bladder augmentation in interstitial cystitis. J Urol 1991; 146: 1113–4PubMed
97.
Pang X, Sant GR, Theoharides TC. Altered expression of bladder mast cell growth factor receptor (c-kit) expression in interstitial cystitis. Urology 1998; 51: 939–44PubMedCrossRef
98.
Conti P, Pang X, Boucher W, et al. Impact of Rantes and MCP-1 chemokines on in vivo basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997; 89: 4120–7PubMed
99.
Bouchelouche K, Alvarez S, Andersen L, et al. Monocyte chemoattractant protein-1 production by human detrusor smooth muscle cells. J Urol 2004 Jan; 171 (1): 462–6PubMedCrossRef
100.
Bouchelouche K, Andresen L, Alvarez S, et al. Interleukin-4 and 13 induce the expression and release of monocyte chemoattractant protein 1, interleukin-6 and stem cell factor from human detrusor smooth muscle cells: synergy with interleukin-1beta and tumor necrosis factor-alpha. J Urol 2006 Feb; 175 (2): 760–5PubMedCrossRef
101.
Christ GJ, Liebert M. Proceedings of the Baltimore smooth muscle meeting: identifying research frontiers and priorities for the lower urinary tract. J Urol 2005 Apr; 173 (4): 1406–9PubMedCrossRef
102.
Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005; 6: 135–42PubMedCrossRef
103.
Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004; 146: 1–12PubMedCrossRef
104.
Serafin WE, Austen KF. Mediators of immediate hypersensitivity reactions. N Engl J Med 1987; 317: 30–4PubMedCrossRef
105.
Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005; 174: 7665–75PubMed
106.
Tamaki M, Saito R, Ogawa O, et al. Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors. J Urol 2004; 172: 945–8PubMedCrossRef
107.
He S, Walls AF. Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. Eur J Pharmacol 1997; 328: 89–97PubMedCrossRef
108.
Batler RA, Sengupta S, Forrestal SG, et al. Mast cell activation triggers a urothelial inflammatory response mediated by tumor necrosis factor-alpha. J Urol 2002; 168: 819–25PubMedCrossRef
109.
Chen MC, Blunt LW, Pins MR, et al. Tumor necrosis factor promotes differential trafficking of bladder mast cells in neurogenic cystitis. J Urol 2006 Feb; 175 (2): 754–9PubMedCrossRef
110.
Marchand JE, Sant GR, Kream RM. Increased expression of substance P receptor-encoding mRNA in bladder biopsies from patients with interstitial cystitis. Br J Urol 1998; 81: 224–8PubMedCrossRef
111.
Lavelle JP, Meyers SA, Ruiz WG, et al. Urothelial pathopysiological changes in feline interstitial cystitis: a human model. Am J Physiol Renal Physiol 2000; 278: F540–53PubMed
112.
Buffington CAT, Chew DJ, Woodworth BE. Animal model of human disease-feline interstitial cystitis. Comp Pathol Bull 1997; 29: 3
113.
Buffington CA, Wolfe SA. High affinity binding sites for [3H] substance P in urinary bladders of cats with interstitial cystitis. J Urol 1998; 160: 605–11PubMedCrossRef
114.
Buffington CA. Comorbidity of interstitial cystitis with other unexplained conditions. J Urol 2004; 172: 1242–8PubMedCrossRef
115.
Westropp JL, Buffington CA. In vivo models of interstitial cystitis. J Urol 2002 Feb; 167 (2 Pt 1): 694–702PubMedCrossRef
116.
Ratliff TL, Klutke CG, Hofmeister M, et al. Short analytical review: role of the immune response in interstitial cystitis. Clin Immunol Immunopathol 1995; 74: 209–16PubMedCrossRef
117.
Bjorling DE, Jerde TJ, Zine MJ, et al. Mast cells mediate the severity of experimental cystitis in mice. J Urol 1999; 162: 231–6PubMedCrossRef
118.
Saban R, Saban MR, Nguyen NB, et al. Neurokinin-1 (NK-1) receptor is required in antigen-induced cystitis. Am J Pathol 2000; 156: 775–80PubMedCrossRef
119.
Malley SE, Vizzard MA. Changes in urinary bladder cytokine mRNA and protein after cyclophosphamide-induced cystitis. Physiol Genomics 2002; 9 (1): 5–13PubMed
120.
Jasmin L, Janni G, Ohara PT, et al. CNS induced neurogenic cystitis is associated with bladder mast cell degranulation in the rat. J Urol 2000; 164: 852–5PubMedCrossRef
121.
Gonzalez RR, Fong T, Belmar N, et al. Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J Urol 2005; 173: 630–4PubMedCrossRef
122.
Theoharides TC, Sant GR. Neuroimmune connections and regulation of function in the urinary bladder. In: Bienenstock J, Goetzl E, Blennerhassett M, editors. Autonomic neuroimmunology. Lausanne: Hardwood Academic Publishers, 2003: 345–69
123.
Pang X, Marchand J, Sant GR, et al. Increased number of substance P positive nerve fibers in interstitial cystitis. Br J Urol 1995; 75: 744–50PubMedCrossRef
124.
Pinter E, Szolcsanyi J. Plasma extravasation in the skin and pelvic organs evoked by antidromic stimulation of the lumbosacral dorsal roots of the rat. Neuroscience 1995; 68: 603–14PubMedCrossRef
125.
Lutgendorf SK, Kreder KJ, Rothrock NE, et al. Stress and symptomatology in patients with interstitial cystitis: a laboratory stress model. J Urol 2000; 164: 1265–9PubMedCrossRef
126.
Spanos C, Pang X, Ligris K, et al. Stress-induced bladder mast cell activation: implications for interstitial cystitis. J Urol 1997; 157: 669–72PubMedCrossRef
127.
Boucher W, Letourneau R, Huang M, et al. Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress. J Urol 2002; 167: 380–4PubMedCrossRef
128.
Alexacos N, Pang X, Boucher W, et al. Neurotensin mediates rat bladder mast cell degranulation triggered by acute psychological stress. Urology 1999; 53: 1035–40PubMedCrossRef
129.
Ercan F, San T, Cavdar S. The effects of cold-restraint stress on urinary bladder wall compared with interstitial cystitis morphology. Urol Res 1999; 27: 454–61PubMedCrossRef
130.
Skofitsch G, Zamir N, Heike CJ, et al. Corticotropin-releasing factor-like immunoreactivity in sensory ganglia and capsaicin sensitive neurons of the rat central nervous system: colocalization with other neuropeptides. Peptides 1985; 6: 307–18PubMedCrossRef
131.
Kawatani M, Suzuki T, de Groat WC. Corticotropin releasing factor-like immunoreactivity in afferent projections to the sacral spinal cord of the cat. J Auton Nerv Syst 1996 Dec 14; 61 (3): 218–26PubMedCrossRef
132.
Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332: 1351–62PubMedCrossRef
133.
Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004; 25: 563–8PubMedCrossRef
134.
Cao J, Boucher W, Donelan JM, et al. Acute stress and intravesical corticotropin-releasing hormone induces mast cell-dependent vascular endothelial growth factor release from mouse bladder explants. J Urol 2006; 176: 1208–13PubMedCrossRef
135.
Klausner AP, Steers WD. Corticotropin releasing factor: a mediator of emotional influences on bladder function. J Urol 2004; 172: 2570–3PubMedCrossRef
136.
Chai TC, Keay S. New theories in interstitial cystitis. Nat Clin Pract Urol 2004 Dec; 1 (2): 85–9PubMedCrossRef
137.
Herrera GM, Braas KM, May V, et al. PACAP enhances mouse urinary bladder contractility and is upregulated in micturition reflex pathways after cystitis. Ann N Y Acad Sci 2006 Jul; 1070: 330–6PubMedCrossRef
138.
Theoharides TC, Sant GR. New agents for the medical treatment of interstitial cystitis. Exp Opin Invest Drugs 2001; 10: 521–46CrossRef
139.
Rovner E, Propert KJ, Brensinger C, et al. Treatments used in women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. Urology 2000; 56: 940–5PubMedCrossRef
140.
Theoharides T, Sant GR. Immunomodulators for the treatment of interstitial cystitis. Urology 2005; 65: 633–8PubMedCrossRef
141.
Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 2003; 170: 810–5PubMedCrossRef
142.
143.
Hupert C, Yacoub M, Turgeon LR. Effect of hydroxyzine on morphine analgesia for the treatment of postoperative pain. Anesth Analg 1980; 59: 690–6PubMedCrossRef
144.
Bouchelouche K, Nordling J, Hald T, et al. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J Urol 2001; 166: 1734–7PubMedCrossRef
145.
Anderson VR, Perry CM. Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis. Drugs 2006; 66 (6): 821–35PubMedCrossRef
146.
Nickel JC, Barkin J, Forrest J, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 2005; 65: 654–68PubMedCrossRef
147.
Theoharides TC, Sant GR. A pilot open label of CystoProtek® in interstitial cystitis. Intl J Immunopathol Pharmacol 2005; 18: 183–8
148.
Theoharides TC, Vakali S, Sant GR. A retrospective open label study of Cystoprotek® in painful bladder syndrome/interstitial cystitis (PBS/IC). NIDDK International Conference: frontiers in painful bladder syndrome and interstitial cystitis; 2006 Oct 25; Bethesda
149.
Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology 1997; 49: 111–3PubMedCrossRef
150.
Kallestrup EB, Jorgensen SS, Nordling J, et al. Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol 2005; 39 (2): 143–7PubMedCrossRef
151.
Yamada T, Murayama T, Andoh M. Adjuvant hydrodistension under epidural anesthesia for interstitial cystitis. Int J Urol 2003; 10: 463–8PubMedCrossRef
152.
Perez-Marrero R, Emerson L, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol 1988; 140 (1): 36–9PubMed
153.
Rossberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis discomfort, side-effects and treatment outcome. Scand J Urol Nephrol 2005; 39: 73–7PubMedCrossRef
154.
Ghoniem GM, McBride D, Sood OP, et al. Clinical experience with multiagent intravesical therapy in interstitial cystitis patients unresponsive to single-agent therapy. World J Urol 1993; 11: 178–82PubMedCrossRef
155.
Melchior D, Packer CS, Johnson TC, et al. Dimethyl sulfoxide: does it change the functional properties of the bladder wall? J Urol 2003 Jul; 170 (1): 253–8PubMedCrossRef
156.
Simon M, McClanahan RH, Shah JF, et al. Metabolism of [3H]pentosan polysulfate sodium (PPS) in healthy human volunteers. Xenobiotica 2005 Aug; 35 (8): 775–84PubMedCrossRef
157.
Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 2005; 65: 45–8PubMedCrossRef
158.
Dragstedt CA, Wells JA, Rocha e Silva M. Inhibitory effect of heparin upon histamine release by trypsin, antigen and proteose. Proc Soc Exp Biol Med 1942; 51: 191–2
159.
Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 1993; 147: 160–3PubMedCrossRef
160.
Nelson RM, Cecconi O, Roberts WG, et al. Heparin oligosac-charides bind L and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253–8PubMed
161.
van Ophoven A, Heinecke A, Hertle L. Safety and efficacy of concurrent application of oral pentosan polysulfate and subcutaneous low-dose heparin for patients with interstitial cystitis. Urology 2005 Oct; 66 (4): 707–11PubMedCrossRef
162.
Kyker KD, Coffman J, Hurst RE. Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder. BMC Urol 2005; 5: 4PubMedCrossRef
163.
Takahashi K, Takeuchi J, Takahashi T, et al. Effects of sodium hyaluronate on epithelial healing of the vesical mucosa and vesical fibrosis in rabbits with acetic acid induced cystitis. J Urol 2001; 166: 710–3PubMedCrossRef
164.
Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol 2002 Feb; 9 (1): 1454–8PubMed
165.
Wammack R, Remzi M, Seitz C, et al. Efficacy of oral doxepin and piroxicam treatment for interstitial cystitis. Eur Urol 2002 Jun; 41 (6): 596–600PubMedCrossRef
166.
Soucy F, Gregoire M. Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. J Urol 2005; 173: 841–3PubMedCrossRef
167.
Stellate C, de Paulis A, Ciccarelli A, et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992; 98: 800–4CrossRef
168.
Forsell T, Ruutu M, Isoniemi H, et al. Cyclosporin in severe interstitial cystitis. J Urol 1996; 155: 1591–3PubMedCrossRef
169.
Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol 2004; 171: 2138–41PubMedCrossRef
170.
Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol 2005 Dec; 174 (6): 2235–8PubMedCrossRef
171.
Moran PA, Dwyer PL, Carey MP, et al. Oral methotrexate in the management of refractory interstitial cystitis. Aust N Z J Obstet Gynaecol 1999; 39: 468–71PubMedCrossRef
172.
Fox DA. Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumor necrosis factor. Arch Intern Med 2000; 160: 437–44PubMedCrossRef
173.
Ross DM, Hughes TP. Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br J Cancer 2004; 90: 12–9PubMedCrossRef
174.
Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535–6PubMedCrossRef
175.
Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des 2003; 9: 1107–13PubMedCrossRef
176.
Nilsson G, Butterfield JH, Nilsson K, et al. Stem cell factor is a chemotactic factor for human mast cells. J Immunol 1994; 153: 3717–23PubMed
177.
de Paulis A, Minopoli G, Arbustini E, et al. Stem cell factor is localized in, released from, and cleaved by human mast cells. J Immunol 1999; 163: 2799–808PubMed
178.
Longley BJ Jr, Morganroth GS, Tyrrell L, et al. Altered metabolism of mast-cell growth factor (c-kit Ligand) in cutaneous mastocytosis. N Engl J Med 1993; 328: 1302–7PubMedCrossRef
179.
Bhol KC, Schechter PJ. Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Br J Dermatol 2005 Jun; 152 (6): 1235–42PubMedCrossRef
180.
Boucher W, Stern JM, Kempuraj D, et al. Intravesical nanocrystalline silver (NCS) inhibits experimental bladder inflammation. NIDDK International Conference: frontiers in painful bladder syndrome and interstitial cystitis; 2006 Oct 26–27; Bethesda (MD)
181.
Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy: review of a new approach. Pharmacol Rev 2003; 55: 241–69PubMedCrossRef
182.
Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004; 10: 620–5PubMed
183.
Lin TJ, Befus AD. Differential regulation of mast cell function by IL-10 and stem cell factor. J Immunol 1997; 159: 4015–23PubMed
184.
Conti P, Kempuraj D, Kandere K, et al. IL-10, an inflammatory/ inhibitory cytokine, but not always. Immunol Lett 2003; 86: 123–9PubMedCrossRef
185.
Peeker R, Haghsheno MA, Holmang S, et al. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol 2000; 164: 1912–6PubMedCrossRef
186.
Mayer R, Propert KJ, Peters KM, et al. A randomized controlled trial of intravesical bacillus Calmette-Guerin for treatment refractory interstitial cystitis. J Urol 2005; 173: 1186–91PubMedCrossRef
187.
Furukido K, Takeno S, Ueda T, et al. Suppression of the Th2 pathway by suplatast tosilate in patients with perennial nasal allergies. Am J Rhinol 2002; 16: 329–36PubMed
188.
Ueda T, Tamaki M, Ogawa O, et al. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T. J Urol 2000; 164: 1917–20PubMedCrossRef
189.
Minogiannis P, El-Mansoury M, Betances JA, et al. Hydroxyzine inhibits neurogenic bladder mast cell activation. Int J Immunopharmacol 1998; 20: 553–63PubMedCrossRef
190.
Lee J, Doggweiler-Wiygul R, Kim S, et al. Is interstitial cystitis an allergic disorder? A case of interstitial cystitis treated successfully with anti-IgE. Int J Urol 2006 May; 13 (5): 631–4PubMedCrossRef
191.
Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000; 52: 673–751PubMed
192.
Kempuraj D, Madhappan B, Christodoulou S, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005; 145: 934–44PubMedCrossRef
193.
Alexandrakis MG, Letourneau R, Kempuraj D, et al. Flavones inhibit proliferation and increase mediator content in human leukemic mast cells (HMC-1). Eur J Haematol 2003; 71: 448–54PubMedCrossRef
194.
Pearce FL, Befus AD, Bienenstock J. Effect of quercetin and other flavonoids on antigen-induced histamine secretion from rat intestinal mast cells. J Allergy Clin Immunol 1984; 73: 819–23PubMedCrossRef
195.
Katske F, Shoskes DA, Sender M, et al. Treatment of interstitial cystitis with a quercetin supplement. Tech Urol 2001; 7: 44–6PubMed
196.
Theoharides TC, Bielory L. Mast cells and mast cell mediators as targets of dietary supplements. Ann Allergy Asthma Immunol 2004; 93 Suppl. 2: S24–34PubMedCrossRef
197.
Theoharides TC, Patra P, Boucher W, et al. Chondroitin sulfate inhibits connective tissue mast cells. Br J Pharmacol 2000; 131: 1039–49PubMedCrossRef
198.
Powell-Boone T, Ness TJ, Cannon R, et al. Menstrual cycle affects bladder pain sensation in subjects with interstitial cystitis. J Urol 2005 Nov; 174 (5): 1832–6PubMedCrossRef
199.
Lentz GM, Bavendam T, Stenchever MA, et al. Hormonal manipulation in women with chronic, cyclic irritable bladder symptoms and pelvic pain. Am J Obstet Gynecol 2002 Jun; 186 (6): 1268–71PubMedCrossRef
200.
Acar D, Cayan S, Aktas S, et al. The effect of tamoxifen on bladder functions and histology, and the role of estrogen receptor beta in a rat chemical cystitis model. Neurourol Urodyn. Epub 2006 Aug 7
201.
Brookoff D, Bennett DS. Neuromodulation in intractable interstitial cystitis and related pelvic pain syndromes. Pain Med 2006 May; 7 Suppl. 1: S166–84CrossRef
202.
Hanno PM, Buehler J, Wein AJ. Use of amitriptyline in the treatment of interstitial cystitis. J Urol 1989; 141: 846–8PubMed
203.
van Ophoven A, Pokupic S, Heinecke A, et al. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol 2004; 172: 533–6PubMedCrossRef
204.
van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. J Urol 2005 Nov; 174 (5): 1837–40PubMedCrossRef
205.
Nickel JC. Opioids for chronic prostatitis and interstitial cystitis: lessons learned from the 11th World Congress on Pain. Urology 2006 Oct; 68 (4): 697–701PubMedCrossRef
206.
Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352: 1324–434PubMedCrossRef
207.
Guay DR. Pregabalin in neuropathic pain: a more “pharmaceutically elegant” gabapentin? Am J Geriatr Pharmacother 2005 Dec; 3 (4): 274–87PubMedCrossRef
208.
Check JH, Katsoff B, Citerone T, et al. A novel highly effective treatment of interstitial cystitis causing chronic pelvic pain of bladder origin: case reports. Clin Exp Obstet Gynecol 2005; 32 (4): 247–9PubMed
209.
Lazzeri M, Beneforti P, Spinelli M, et al. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol 2000; 164: 676–9PubMedCrossRef
210.
Payne CK, Mosbaugh PG, Forrest JB, et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 2005; 173: 1590–4PubMedCrossRef
211.
Smith CP, Nishiguchi J, O’Leary M, et al. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005; 65: 37–41PubMedCrossRef
212.
Kuo HC. Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int 2005; 75 (2): 170–4PubMedCrossRef
213.
Giannantoni A, Costantini E, Di Stasi SM, et al. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 2006 Apr; 49 (4): 704–9PubMedCrossRef
214.
Korting GE, Smith SD, Wheeler MA, et al. A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J Urol 1999; 161: 558–65PubMedCrossRef
215.
Thilagarajah R, Witherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. BJU Int 2001; 87: 207–12PubMedCrossRef
216.
Cappelleri JC, Ioannidis JP, Schmid CH, et al. Large trials vs meta-analysis of smaller trials: how do their results compare? JAMA 1996 Oct 23; 276 (16): 1332–8PubMedCrossRef
Metadata
Title
Treatment Approaches for Painful Bladder Syndrome/Interstitial Cystitis
Author
Dr Theoharis C. Theoharides
Publication date
01-02-2007
Publisher
Springer International Publishing
Published in
Drugs / Issue 2/2007
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200767020-00004

Other articles of this Issue 2/2007

Drugs 2/2007 Go to the issue

Therapy In Practice

Guidelines and Recommendations for the Management of Anaemia in Patients with Lymphoid Malignancies

Therapy In Practice

Optimising Antimicrobial Therapy in Diabetic Foot Infections

Adis Drug Profile

Selegiline Transdermal System: In the Treatment of Major Depressive Disorder

Adis Drug Evaluation

Imatinib

Adis Drug Profile

Selegiline Transdermal System In the Treatment of Major Depressive Disorder

Therapy In Practice

Clinical and Therapeutic Issues for Herpes Simplex Virus-2 and HIV Co-Infection